Clinical research company IQVIA (NYSE: IQV) reported Q3 2026 results topping the market’s revenue expectations, with sales up 8% year on year to $4.43 billion. The company expects the full year’s revenue to be around $17.43 billion, close to analysts’ estimates. Its non-GAAP profit of $3.34 per share was 2% above analysts’ consensus estimates.

Is now the time to buy IQV? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

IQVIA delivered an 8% year-over-year revenue increase in Q3, with results that outpaced Wall Street expectations and prompted a positive market reaction. Management attributed this performance to accelerated growth in both clinical and commercial segments, underscored by robust operational execution and higher win rates. CEO Ari Bousbib highlighted the company’s increased adoption of artificial intelligence (AI) solutions, which played a significant role in winning new business and improving productivity. Bousbib described clinical bookings as the strongest in four years, citing expanded use of AI-driven tools as a differentiator for clients seeking faster, more efficient studies.

Looking ahead, IQVIA’s slightly raised full-year guidance is supported by sustained demand in both R&D and commercial solutions, as well as ongoing momentum in AI-driven offerings. Management emphasized the favorable funding environment for biotech and continued growth in clinical trial starts as key drivers of future growth. CFO Michael J. Fedock noted that operational improvements and AI-powered productivity programs are expected to support margin stability, even as the company navigates potential headwinds from foreign exchange and pass-through revenue mix. Bousbib stated, “AI is not just another technology—it is a new way of doing business,” underlining its central role in IQVIA’s strategy.

Key insights from management’s remarks

Management cited AI adoption, robust clinical bookings, and strong commercial pipelines as key drivers of the quarter’s performance and the company’s improved outlook.

• AI-driven differentiation: IQVIA’s expanded deployment of AI-powered agents and analytics platforms has helped secure large clinical and commercial contracts, with management calling out a 9-month timeline reduction for a recent autoimmune study and improved client decision-making in commercial engagements.
• Clinical bookings surge: The company achieved its highest clinical net new bookings in four years, up 15% year over year, which management linked to both improved win rates and a healthier funding environment for biotech and emerging biopharma (EBP) clients.
• Operational margin improvements: Despite headwinds from higher pass-through revenues, operational efficiencies—driven by AI-enabled productivity and cost containment—contributed to an 80 basis point underlying improvement in adjusted EBITDA margin, offsetting non-operational pressures.
• Commercial solutions momentum: All three commercial subsegments—information, analytics and consulting, and engagement-focused services—showed healthy growth, with pipelines at record levels and new drug approvals up more than 40% year to date, supporting future launch activity.
• Resilient backlog and contract discipline: Management performed a detailed review and adjustment of inactive trials in the backlog, removing projects with over 18 months of inactivity to provide clearer visibility, while emphasizing that only contracted work is counted as backlog, ensuring transparency and accuracy.

Drivers of future performance

IQVIA’s outlook is shaped by ongoing AI integration, strong biotech funding, and expectations of stable margins amid continued demand for clinical and commercial services.

• AI and digital productivity: Management expects accelerated deployment of AI agents in both client-facing and internal workflows to drive operational efficiency, shorten timelines, and support higher-margin service delivery, with continued investment in proprietary data and analytics platforms.
• Biotech funding and clinical demand: The robust funding environment for biotech—up 85% year-over-year—and a high volume of new drug approvals are anticipated to sustain strong demand for clinical trial services, especially among emerging biopharma clients, which tend to outsource R&D at higher rates.
• Margin stability and headwinds: While operational improvements and AI-driven productivity are expected to support margin stability, management flagged ongoing headwinds from foreign exchange and the mix of pass-through revenues, advising investors to focus on EBITDA dollars as a more meaningful measure of performance.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) whether AI-enabled solutions continue to drive incremental clinical bookings and shorten project timelines, (2) sustained growth in commercial pipelines as new drug launches progress, and (3) the impact of further operational efficiency initiatives on EBITDA margin stability. Additionally, we will track any changes in biotech funding trends and the pace of backlog conversion as key indicators of underlying demand.

IQVIA currently trades at $284.08, up from $273.49 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.